Last updated: February 27, 2026
What is the current development status of Darusentan?
Darusentan is an endothelin-A receptor antagonist primarily developed for resistant hypertension and heart failure. The drug was initially investigated by Gilead Sciences, which developed it through Phase III trials. The key milestones include:
- Phase III trials completed in the early 2010s, showing reductions in blood pressure in hypertensive patients resistant to standard therapy.
- Regulatory submissions were made in the U.S. and Europe; however, the FDA did not approve Darusentan for resistant hypertension due to concerns about safety and efficacy.
- Gilead shifted its focus post-approval setback, ceasing further development around 2013.
Currently, no ongoing clinical trials by major pharmaceutical firms are publicly active, indicating the compound remains inactive in late-stage development for this indication.
What are the challenges faced during Darusentan development?
- Safety concerns: In Phase III studies, adverse events such as fluid retention, edema, and liver enzyme elevations were noted.
- Efficacy issues: While blood pressure reductions were observed, they were not deemed enough to outweigh safety risks or to meet regulatory expectations.
- Market considerations: The resistance to hypertension market grows competitive, with multiple proven therapies available and a limited pipeline for endothelin receptor-targeting drugs.
How does Darusentan compare with other endpoints and competitors?
| Aspect |
Darusentan |
Competitive Drugs |
| Therapeutic class |
Endothelin-A receptor antagonist |
Multiple, including ARBs, ACE inhibitors |
| Approved indications |
No current approval |
Hypertension, pulmonary arterial hypertension |
| Safety profile |
Concerns about edema, liver toxicity |
Generally well-tolerated, except specific cases |
| Efficacy |
Moderate blood pressure reduction |
Variable, depends on drug class |
No drugs in the same class hold FDA approval for resistant hypertension, though others like bosentan are approved for pulmonary arterial hypertension. This niche remains unoccupied due to safety concerns and efficacy thresholds.
What is the market outlook for Darusentan?
The global resistant hypertension market was valued at approximately $2.1 billion in 2021, expected to grow at about 7% annually through 2028. Key factors influencing Darusentan’s potential include:
- Market competition: Many drugs are available, including ARBs, ACE inhibitors, and diuretics, with established safety profiles.
- Unmet needs: Limited options exist for specific resistant hypertension subgroups. Candidates with better safety profiles could fill this gap.
- Regulatory environment: Rigid safety thresholds raise barriers for approval, especially following prior setbacks with Darusentan.
Given the current development status and safety hurdles, Darusentan's market opportunity appears limited unless new formulations or indications emerge.
What opportunities could stretch Darusentan’s potential?
- New formulations: Extended-release or targeted delivery mechanisms to mitigate side effects.
- Novel indications: Exploration in conditions like pulmonary arterial hypertension, where endothelin antagonists are established.
- Combination therapy: Use with other antihypertensives to reduce dosages and adverse reactions.
- Biomarker-driven patient selection: Using genetic or biomarker profiles to identify subpopulations that may respond better.
Development pathways are constrained by past safety issues, but strategic repositioning remains a possibility.
What strategic moves should stakeholders consider?
- Pharmaceutical firms could revisit Darusentan for pulmonary hypertension, leveraging existing knowledge from bosentan and ambrisentan.
- Partnering with biotech companies innovating drug delivery may mitigate safety concerns.
- Investment in biomarker research could identify responders, expanding usable patient populations.
Further R&D efforts should align with unmet needs and safety improvements to unlock market value.
Key Takeaways
- Darusentan has completed Phase III trials but failed FDA approval due to safety and efficacy concerns.
- No active development programs are publicly ongoing, limiting near-term commercial prospects.
- The drug faces intense competition from established antihypertensives, within a cautious regulatory environment.
- Market growth potential exists in specific niches like pulmonary arterial hypertension, contingent on product repositioning.
- Strategic re-evaluation or repositioning is essential for any future market entry.
FAQs
-
Will Darusentan ever return to the market?
Its return depends on addressing safety concerns through reformulation or new indications. No public plans currently exist.
-
Can Darusentan be repurposed for other conditions?
Repositioning for pulmonary arterial hypertension or other endothelin-related disorders is a consideration, pending positive safety profiles.
-
What are the main safety issues associated with Darusentan?
Edema, fluid retention, and liver enzyme elevations were predominant during clinical trials.
-
Are there any ongoing clinical trials involving Darusentan?
No publicly known trials are active; development suspended since the early 2010s.
-
How does Darusentan’s market size compare to similar drugs?
Its potential market is niche, mainly in resistant hypertension, estimated at $2 billion globally but limited by safety and efficacy barriers.
References
[1] Gilead Sciences. (2013). Annual Report 2013.
[2] MarketWatch. (2022). Resistant Hypertension Market Size & Growth.
[3] U.S. Food & Drug Administration. (2013). FDA Complete Response Letter.
[4] IQVIA. (2022). Global Hypertension Market Data.
[5] European Medicines Agency. (2012). Drug Evaluation Reports.
